EGFR and neoplasm: Despite these achievements, recent studies have shown that treatment of EGFR TKIs leads to the development of acquired resistance through target gene mutations, activation of alternative RTK signaling pathways, histological transformation, or intra-tumor heterogeneity (Chong and Janne, 2013).